European Medicines Agency issues restrictions on cyproterone medicines

The restrictions are being introduced after a safety review found that high-dose cyproterone medicines may increase risk for meningioma.
The restrictions are being introduced after a safety review found that high-dose cyproterone medicines may increase risk for meningioma.